G Barosi

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi Emerging targeted therapies in myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy
    Expert Rev Hematol 5:313-24. 2012
  2. ncbi Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Centre for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    PLoS ONE 7:e35631. 2012
  3. ncbi SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Ann Hematol 91:875-88. 2012
  4. ncbi Management of myeloproliferative neoplasms: from academic guidelines to clinical practice
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, Pavia, Italy
    Curr Hematol Malig Rep 7:50-6. 2012
  5. ncbi Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
    G Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Haematol 114:78-83. 2001
  6. ncbi Myelofibrosis with myeloid metaplasia
    Giovanni Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Hematol Oncol Clin North Am 17:1211-26. 2003
  7. ncbi Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 90:1236-57. 2005
  8. ncbi Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia
    Giovanni Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Br J Haematol 124:618-25. 2004
  9. ncbi Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:717-41. 2004
  10. ncbi A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
    G Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo, Pavia, Italy
    Leukemia 21:277-80. 2007

Detail Information

Publications44

  1. ncbi Emerging targeted therapies in myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy
    Expert Rev Hematol 5:313-24. 2012
    ..Epigenetic drugs (demethylating agents and histone deacetylase inhibitors) have displayed only minor effects on the disease symptoms. Relenting disease progression remains an unmet clinical need...
  2. ncbi Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Centre for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    PLoS ONE 7:e35631. 2012
    ..In the WHO diagnostic classification, prefibrotic myelofibrosis (pre-MF) is included in the category of primary myelofibrosis (PMF). However, strong evidence for this position is lacking...
  3. ncbi SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Ann Hematol 91:875-88. 2012
    ..In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive)...
  4. ncbi Management of myeloproliferative neoplasms: from academic guidelines to clinical practice
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, Pavia, Italy
    Curr Hematol Malig Rep 7:50-6. 2012
    ..Allogeneic stem cell transplantation remains the only potentially curative approach...
  5. ncbi Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
    G Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Haematol 114:78-83. 2001
    ..The unexpected observation of leucocytosis and thrombocytosis suggests biological studies and better criteria for selection of patients for treatment...
  6. ncbi Myelofibrosis with myeloid metaplasia
    Giovanni Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Hematol Oncol Clin North Am 17:1211-26. 2003
    ..Thalidomide has been tested in numerous series, and its capacity to improve anemia and thrombocytopenia while reducing splenomegaly has been documented...
  7. ncbi Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 90:1236-57. 2005
    ..By using a systematic literature review and an explicit approach to consensus among experts, recommendations for the key therapeutic decisions in patients with nodal indolent NHL are provided...
  8. ncbi Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia
    Giovanni Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Br J Haematol 124:618-25. 2004
    ..These results document that neoangiogenesis is an integral component of spleen re-localization of haematopoietic stem cells and suggest a cellular mechanism for spleen neoangiogenesis...
  9. ncbi Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:717-41. 2004
    ....
  10. ncbi A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
    G Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo, Pavia, Italy
    Leukemia 21:277-80. 2007
    ....
  11. ncbi Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood 106:2849-53. 2005
    ..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM...
  12. ncbi Strategies for dissemination and implementation of guidelines
    G Barosi
    Unit of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Neurol Sci 27:S231-4. 2006
    ..A positive effect was reported from a validation study of a multifaceted strategy for stroke care ICP implementation in Italy...
  13. ncbi Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia and Second Division of Hematology, Ospedale San Martino, Viale Golgi 19, 27100 Genoa, Italy
    Curr Opin Hematol 13:74-8. 2006
    ....
  14. ncbi Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies
    Giovanni Barosi
    Laboratorio di Informatica Medica, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    Leuk Lymphoma 43:2301-7. 2002
    ..The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug...
  15. ncbi JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    Blood 110:4030-6. 2007
    ..We conclude that JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF...
  16. ncbi High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy
    Giovanni Barosi
    Laboratorio di Informatica Medica, IRCCS Policlinico S Matteo, p le Golgi 3, 27100 Pavia, Italy
    Haematologica 87:472-8. 2002
    ..In Italy, typical HFE mutations account for only 64% of the cases with overt hereditary hemochromatosis (HH), and a common HFE-unrelated disease was hypothesized...
  17. ncbi The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia
    G Barosi
    Laboratorio di Informatica Medica, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Haematol 104:730-7. 1999
    ..The use of this definition will help to standardize the conduct and reporting of clinical studies and should help practitioners in clinical practice...
  18. ncbi Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines
    G Barosi
    Laboratory of Medical Informatics, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    J Clin Oncol 17:2954-70. 1999
    ....
  19. ncbi Therapeutic approaches in myelofibrosis
    Giovanni Barosi
    IRCCS Policlinico S Matteo Foundation, Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Viale Golgi 19, 27100 Pavia, Italy
    Expert Opin Pharmacother 12:1597-611. 2011
    ..These new drugs will give physicians more options to tailor therapeutic choice in this challenging disease...
  20. ncbi Novel strategies for patients with chronic myeloproliferative disorders
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Pavia, Italy
    Curr Opin Hematol 16:129-34. 2009
    ..This review focuses on new strategies for unmet clinical needs and on new targeted therapies in classical Philadelphia-negative myeloproliferative neoplasms...
  21. ncbi Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Blood 113:4829-33. 2009
    ..The combined use of these response definitions should help standardize the design and reporting of clinical studies...
  22. ncbi Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia
    G Barosi
    Laboratory of Medical Informatics, the Unit of Clinical Immunology and Immunohematology, The Transfusion Service, Policlinico San Matteo, Pavia, Italy
    Blood 98:3249-55. 2001
    ..In conclusion, the absolute number of CD34(+) circulating cells allows MMM to be distinguished from other Ph(-) CMDs; it is strongly associated with the extent of myeloproliferation and predicts evolution toward blast transformation...
  23. ncbi Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 91:96-103. 2006
    ..Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated...
  24. ncbi Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S. Matteo, Pavia, Italy
    Am J Med 111:130-9. 2001
    ..The apparent increase in recurrence after interruption of therapy needs to be investigated more thoroughly before low-molecular-weight heparin can be recommended routinely...
  25. ncbi Cost-effectiveness of interferon alfa in chronic myelogenous leukemia
    N L Liberato
    Laboratory of Medical Informatics, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    J Clin Oncol 15:2673-82. 1997
    ..To evaluate the cost-effectiveness of interferon alfa (IFN alpha) treatment of patients with chronic myelogenous leukemia relative to conventional chemotherapy...
  26. ncbi Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial
    Monia Marchetti
    Laboratory of Medical Informatics, Unit of Clinical Immunology and Immunohematology, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 22:424-31. 2004
    ..CONCLUSION: Low-dose thalidomide displays an acceptable toxicity profile and provides an objective and subjective advantage to a relevant portion of MMM patients...
  27. ncbi Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery
    M Marchetti
    Laboratory of Medical Informatics, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Transfusion 40:673-81. 2000
    ..Recombinant human erythropoietin (epoetin) has the potential to decrease perioperative need for allogeneic blood during CABG, but its high cost calls for a careful economic evaluation before it can be recommended for widespread use...
  28. ncbi Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
    G Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Cancer 78:781-7. 1998
    ..More tailored utilization of the drug and better consideration of predictive response indicators may lead to an effective, blood-sparing alternative...
  29. ncbi Regulation of erythropoietin production in a case of congenital erythropoietin-dependent pure erythrocytosis
    C Borgna-Pignatti
    Department of Pediatrics, University of Verona, IRCCS Policlinico S Matteo, Pavia, Italy
    Am J Hematol 46:348-53. 1994
    ....
  30. ncbi Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
    Emilio Paolo Alessandrino
    Divisione di Ematologia, IRCCS Policlinico S. Matteo, Pavia, Italy
    Haematologica 87:1286-306. 2002
    ..INTERPRETATION AND CONCLUSIONS: Using evidence and consensus, recommendations for the treatment of MDS were issued. Statements were graded according to the strength of the supporting evidence and uncertainty was explicitly declared...
  31. ncbi Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematol
    Pier Luigi Zinzani
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, 27100, Pavia, Italy
    Haematologica 93:1364-71. 2008
    ....
  32. ncbi Deciding when to intervene: a Markov decision process approach
    P Magni
    Dipartimento di Informatica e Sistemistica, Universita degli Studi di Pavia, Via Ferrata 1, I 27100, Pavia, Italy
    Int J Med Inform 60:237-53. 2000
    ..The calculations are carried out with DT-Planner, a graphical decision aid specifically built for dealing with dynamic decision processes...
  33. ncbi Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, and Department of Computer Science and Systems, University of Pavia, Pavia, Italy
    QJM 94:365-72. 2001
    ..Screening for factor V Leiden and prothrombin G20210A, with prolonged prophylaxis of double carriers, is cost-effective in most patients with VTE...
  34. ncbi Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
    Ercole Brusamolino
    Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Universita di Pavia, Pavia 27100, Italy
    Haematologica 94:550-65. 2009
    ..All fertile patients should be informed of the possible effects of therapy on gonadal function and fertility preservation measures should be taken before the initiation of therapy...
  35. ncbi Clinical and economic impact of epoetins in cancer care
    Monia Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico San Matteo, Pavia, Italy
    Pharmacoeconomics 22:1029-45. 2004
    ..In the near future we expect that a wider range of epoetins, drug patent expiry, a more appropriate patient selection criteria and an improved dosage schedule may help increase the efficiency of cancer-related anaemia management...
  36. ncbi Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis
    Rita Campanelli
    Laboratory of Clinical Epidemiology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Cytokine 53:100-6. 2011
    ....
  37. ncbi Small-dose iron tolerance test and body iron content in normal subjects
    A Costa
    Dipartimento di Medicina Interna e Terapia Medica Sez Clinica Medica 2, IRCCS Policlinico S Matteo, Pavia, Italy
    Eur J Haematol 46:152-7. 1991
    ..The threshold-dependent sensitivity, simplicity, and repeatability of this method favor its becoming a useful technique for studying the up-regulation of iron absorption in normal subjects and in pathological conditions...
  38. ncbi The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia
    Vittorio Rosti
    Transplant Research Area, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood Cells Mol Dis 38:280-6. 2007
    ..We studied the expression of the chemokine receptor CXCR4 on circulating CD34+ cells of patients with myelofibrosis with myeloid metaplasia (MMM), and examined its relationship to the severity of disease...
  39. ncbi Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Nicola Lucio Liberato
    Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo, Pavia, Italy
    J Clin Oncol 25:625-33. 2007
    ..To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in women with high-risk human epidermal growth factor receptor 2 (HER2) -positive early breast cancer...
  40. ncbi Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options
    Ruben A Mesa
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Best Pract Res Clin Haematol 19:495-517. 2006
    ..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM...
  41. ncbi Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Thromb Haemost 84:752-7. 2000
    ..34% per year or recurrent DVT at a rate lower than 9% in the first 2 years. The screening policy was cost-saving if restricted to patients with idiopathic DVT and compliant to warfarin therapy...
  42. ncbi In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Claudio Grignani
    Department of Internal Medicine, University of Pavia IRCCS Policlinico San Matteo Foundation, Pavia, Italy
    Platelets 20:131-4. 2009
    ..We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact...
  43. ncbi Idiopathic myelofibrosis
    Giovanni Barosi
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo, Pavia, Italy
    Semin Hematol 42:248-58. 2005
    ..The use of reduced intensity conditioning (RIC) regimens has resulted in prolonged survival and lower transplant-related mortality...
  44. ncbi Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
    Tiziano Barbui
    Unit of Clinical Epidemiology Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 29:761-70. 2011
    ..The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years...